HPRA Drug Safety Newsletter Edition 82
Download:
hpra-drug-safety-newsletter-edition-82.pdf
217 KB
The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines:
- Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment
- Gabapentin – respiratory depression without concomitant opioid use
- Amoxicillin; co-amoxiclav – very rare reports of DRESS (drug reaction with eosinophilia and systemic symptoms)
- Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter
« Back